Summary & Overview
HCPCS A2031: Mirodry Wound Matrix, Per Square Centimeter
HCPCS Level II code A2031 designates the Mirodry wound matrix billed per square centimeter as an add-on supply to a primary wound procedure. Nationally, this code captures use of a biologic wound matrix product that supports tissue regeneration in complex or hard-to-heal wounds. Its use affects product-level billing across outpatient wound care settings and informs coverage and payment decisions for advanced wound therapies.
Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the product, typical sites of service, and what to expect in payer coverage discussions. The publication summarizes benchmarks where available, outlines common billing modifiers associated with add-on product billing, and highlights policy and coding considerations relevant to wound care supply reimbursement.
This national perspective is intended to help billing professionals, clinical administrators, and policy analysts understand the role of HCPCS Level II code A2031 in documenting and billing biologic wound matrix use, and to provide clarity on the operational and policy issues that typically arise when billing for add-on wound products.
Billing Code Overview
HCPCS Level II code A2031 describes the Mirodry wound matrix billed per square centimeter as an add-on, list separately in addition to primary procedure. This code represents a biologic wound matrix product used in wound care management to support tissue regeneration and wound closure.
Service Type: Wound care product — biologic wound matrix
Typical Site of Service: Outpatient wound care clinics, hospital outpatient departments, physician offices, and specialized wound centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a non-healing full-thickness cutaneous wound (for example, a diabetic foot ulcer or a chronic venous leg ulcer) that has failed conservative therapy and requires advanced wound care. The wound care specialist or plastic surgeon evaluates wound size, depth, infection status, and vascular supply in an outpatient wound clinic or ambulatory surgery center. After debridement and optimization of the wound bed, the provider applies a biologic or synthetic wound matrix product billed as an add-on supply by area. The product described by A2031 is billed per square centimeter in addition to the primary procedure (for example, debridement or graft placement). Typical workflow steps: wound assessment and measurement; pre-procedure imaging or vascular assessment as indicated; sharp/surgical debridement under local or monitored anesthesia; application of the wound matrix to the prepared wound bed; securement with dressings or grafting materials; documentation of square centimeters of product used and clinical rationale; post-procedure dressing and follow-up wound care visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; only if payer requires a placeholder and no other modifier applies |
22 | Increased procedural services | Use when services require substantially greater work than typical (e.g., extensive debridement plus complex matrix application) |
23 | Unusual anesthesia | Use when procedure requires general or regional anesthesia for reasons unrelated to the procedure's complexity |
52 | Reduced services | Use when the product application or associated procedure is partially reduced or not completed as originally planned |
53 | Discontinued procedure | Use when procedure is started but terminated for patient-related or clinical reasons before completion |
54 | Surgical care only | Use when billing is for the surgical portion and other providers bill pre/post-operative care |
55 | Post-operative management only | Use when billing is for post-operative care only, not applicable to supply billing typically but applicable to accompanying services |
56 | Pre-operative management only | Use when billing is for pre-op management only, rarely used with supply code but applicable to associated services |
62 | Two surgeons | Use when two surgeons of different specialties work together and both document active participation in the procedure |
78 | Return to OR for related procedure during global period | Use when patient requires a related return procedure during the global period |
AS | Physician assistant, nurse practitioner, clinical nurse specialist services for Medicare | Use to indicate services furnished by these non-physician clinicians when applicable |
NU | New equipment | Use when the supply is newly provided; may be used by some payers to indicate non-rental new prosthetic/supply |
QK | Medical direction of two, three, or four CRNAs | Use when the anesthesiologist medically directs multiple CRNAs for anesthesia associated with the procedure |
QX | CRNA service furnished under qualified supervision by physician | Use when CRNA furnishes anesthesia under physician supervision |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
174N00000X | General Surgery | Commonly performs debridement and wound matrix application in OR or outpatient settings |
208000000X | Podiatry | Performs wound care and matrix application for foot and ankle wounds, including diabetic ulcers |
163W00000X | Plastic Surgery | Manages complex soft tissue reconstruction and grafting where wound matrices are used |
103T00000X | Family Medicine | Provides outpatient wound care and may apply wound matrices in clinic settings |
207V00000X | Dermatology | Treats chronic skin wounds and applies biologic/synthetic matrices in clinic |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
L97.421 | Non-pressure chronic ulcer of left ankle with necrosis of muscle | Chronic lower-extremity ulcer requiring debridement and matrix placement to promote healing |
L97.411 | Non-pressure chronic ulcer of right ankle with necrosis of muscle | Same as above for the contralateral limb; wound matrix used after wound bed preparation |
E11.621 | Type 2 diabetes mellitus with foot ulcer | Diabetic foot ulcers commonly require advanced wound matrices after debridement to encourage healing |
I83.019 | Varicose veins of right lower extremity with ulcer, unspecified | Venous stasis ulcers often managed with debridement and biologic/synthetic matrices as adjuncts to compression therapy |
L89.153 | Pressure ulcer of sacrum, stage 3 | Deep pressure ulcers may be managed with wound matrix products following debridement and infection control |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
11042 | Debridement, subcutaneous tissue (eg, muscle and/or fascia, first 20 sq cm or less) | Commonly billed for surgical debridement prior to application of a wound matrix; prepares wound bed for matrix placement |
11043 | Debridement, muscle and/or fascia (first 20 sq cm or less) | Used when deeper debridement is required before matrix application |
97605 | Negative pressure wound therapy (NPWT) using disposable device, total wound(s) surface area up to and including 50 sq cm | May be used before or after matrix placement to assist with wound healing and secure grafts or matrices |
15271 | Placement of a biologic implant (eg, acellular dermal matrix), lower extremity wounds, single layer, first 25 sq cm | Representative code for placement of biologic matrix products; A2031 is an add-on supply billed per sq cm in addition to a primary procedure like this |
15732 | Muscle, myocutaneous or fasciocutaneous flap; trunk | Used in more complex reconstruction when flaps are performed in combination with wound matrices for definitive closure |